2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…2018 American Transplant Congress
TORC1 Inhibition Protects Activated Human Regulatory T Cells from Self-Inflicted Damage via Granzyme B
Transplantation Research Center, BWH, Harvard Medical School, Boston, MA.
The safety and efficacy of adoptive transfer of regulatory T cells (Tregs) are being extensively investigated in ongoing clinical trials. However, these trials have been…2017 American Transplant Congress
Potential Mechanism Involving Regulatory T Cells in Induction of Tolerance in Mouse Vascularized Composite Allotransplantation Under Combined Costimulation Blockade.
Background: Role of Regulatory T cells in vascularized composite allotransplantation (VCA) remains to be elucidated. In this study, we investigate potential mechanism involved in Tregs…2017 American Transplant Congress
Rapamycin Directly Alters Human Endothelial Cell Alloimmunogenicity.
The mTOR inhibitor rapamycin (Rapa) is known to suppress T cell function. However, many of its in vivo effects, particularly its synergistic effects with costimulation…2017 American Transplant Congress
Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial.
MRC Centre for Transplantation, King's College London, London, United Kingdom
Aim“ThRIL” is a multiple site, open-label, uncontrolled, phase I clinical trial assessing the safety and applicability of a CD4+CD25+FOXP3+ regulatory T cell (Treg) immunotherapy in…2017 American Transplant Congress
IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.
Department of Surgery, Duke University School of Medicine, Durham, NC
Transplant patients treated with belatacept without depletional induction show high rates of costimulation blockade resistant rejection (CoBRR); this has been associated with CD57+ T cells.…2017 American Transplant Congress
The mTOR Signal Regulates Myeloid Derived Suppressor Cells Differentiation and Immunosuppressive Function in Acute Kidney Injury.
Urology, Zhongshan Hospital, Fudan University, Shanghai, China
The mammalian target of rapamycin (mTOR) is a serine–threonine kinase that senses various environmental stimuli. The mTOR signal controls innate and adaptive immune response in…2017 American Transplant Congress
Inhibition of Multiple Nodes in the PI3K/Akt/mTOR Pathway Synergistically Suppresses Epstein-Barr Virus B Cell Lymphomas.
Division of Abdominal Transplantation, Stanford School of Medicine, Palo Alto, CA
Treating post-transplant lymphoproliferative disorders (PTLD) remains a clinical challenge due to adverse effects such as graft rejection. mTOR inhibitors, including rapamycin (RAPA), have shown both…2017 American Transplant Congress
Timing of Mesenchymal Stem Cell Infusions Affects Rejection Free and Overall Islet Allograft Survival.
We recently demonstrated that autologous, bone marrow-derived mesenchymal stem cells (MSC) promote allogeneic islet engraftment and survival in a streptozotocin induced, cynomolgus monkey model of…
American Transplant Congress abstracts